New drug shows promise for regrowing hair in severe alopecia

NCT ID NCT06018428

Ongoing Disease control Sponsor: Q32 Bio Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called bempikibart (ADX-914) in 75 adults with severe alopecia areata, a condition causing significant scalp hair loss. In the first part, some participants received the drug and some a placebo to see if it helps hair regrow. The second part gives the drug to all participants to check safety and effectiveness over a longer period.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: bempikibart (ADX-914)
What this could lead to: If successful, this could offer a new treatment option for people with severe alopecia areata, potentially regrowing significant scalp hair.
What could go wrong: This is an early Phase 2 trial with only 75 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia alopecia areata dermatitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALOPECIA AREATA

Contacts and locations

Show contact details

Locations

Austin, Texas

Austin, Texas, 78759, United States
Bexley, Ohio

Bexley, Ohio, 43209, United States
Bowling Green, Kentucky

Bowling Green, Kentucky, 42104, United States
Burlington, Massachusetts

Burlington, Massachusetts, 01805, United States
Clarksville, Indiana

Clarksville, Indiana, 47129, United States
Clinical Trials

Canton, Ohio, 44718, United States
Clinical Trials

Calgary, Alberta, T1Y 0B4, Canada
Clinical Trials

Winnipeg, Manitoba, R3M 3Z4, Canada
Clinical Trials

Oakville, Ontario, L6J 7W5, Canada
Clinical Trials

Peterborough, Ontario, K9J 5K2, Canada
Clinical Trials

Waterloo, Ontario, N2J 1C4, Canada
Encinitas, California

Encinitas, California, 92024, United States
Fayetteville, Arkansas

Fayetteville, Arkansas, 72703, United States
Fountain Valley, California

Fountain Valley, California, 92708, United States
Frisco, Texas

Frisco, Texas, 75034, United States
Hot Springs, Arkansas

Hot Springs, Arkansas, 71913, United States
Houston, Texas

Houston, Texas, 77056, United States
Jordan, Utah

Jordan, Utah, 84095, United States
Lomita, California

Lomita, California, 90717, United States
Mason, Ohio

Mason, Ohio, 45040, United States
Mayfield Heights, Ohio

Mayfield Heights, Ohio, 44124, United States
Miami, Florida

Miami, Florida, 33173, United States
New Haven, Connecticut

New Haven, Connecticut, 06519, United States
New York, New York

New York, New York, 10012, United States
New York, New York

New York, New York, 10023, United States
Portland, Oregon

Portland, Oregon, 97225, United States
San Antonio, Texas

San Antonio, Texas, 78213, United States
Scottsdale, Arizona

Scottsdale, Arizona, 85255, United States
Spokane, Washington

Spokane, Washington, 99202, United States
Tampa, Florida

Tampa, Florida, 33613, United States
Troy, Michigan

Troy, Michigan, 48084, United States
Warren, Michigan

Warren, Michigan, 48192, United States
Wilmington, North Carolina

Wilmington, North Carolina, 28405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.